British recommendations on prevention of coronary heart disease in clinical practice.British Cardiac Society, British Hyperlipidaemia Association,British Hypertension Society,endorsed by the British Diabetic Association.
Cholesterol Treatment Trialists’ Collaborators. Efﬁcacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.Lancet 2005;366:1267–78.
for Clinical Excellence. Clinical Guideline H.
(2006). Primatesta P,Poulter NR.Levels of dyslipidaemia and improvement in its management
Primatesta P,Poulter NR.Lipid concentrations and the use of lipid lowering drugs:evidence from a national cross sectional survey.BMJ
(1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease:the Scandinavian Simvastatin Survival Study
Scottish Intercollegiate Guidelines Network. Lipids and the Primary Prevention of Coronary Heart Disease.SIGN Publication No.40. Edinburgh:Royal College of Physicians,
(1995). SM,Ford I,Isles CG,Lorimer AR, MacFarlane PW,McKillop JH,Packard CJ.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.West of Scotland Coronary Prevention Study Group.
Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals:a randomized placebo-controlled trial.
(1998). The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
(2006). Wei L,Macdonald TM,Watson AD,Murphy MJ.Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes:observational study.Pharmacoepidemiol Drug Saf
Wei L,Murphy MJ,Macdonald TM.The impact on cardiovascular events of increasing high-density lipoprotein cholesterol with and without lipid-lowering drugs.Heart